News

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...
Zacks Investment Research on MSN1d
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...
Why Novo Nordisk Stock Plummeted Today
Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...
Nasdaq28d
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
NVO Return on Equity Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks ...
Zacks Investment Research on MSN7d
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...